e-drug
[Top] [All Lists]

[e-drug] Price discount for biosimilar infliximab obtained by pool procurement (2)

E-DRUG: Price discount for biosimilar infliximab obtained by pool procurement 
(2)
------------------------------------------------------------------------------------------------------------

Very interesting, but realize that after these big, double discounts, a lot of 
profit may well remain. 
Manufacturing costs in volume are very low; so the volume matters a lot. 
As for R&D costs, what matters to companies is their net R&D costs, after all 
tax credits, deductions and after all research supported by the public. 

Overall, 84 percent of all funds to discover new medicines comes from public 
sources. 
See Chapter 3 in 
http://announcementsfiles.cohred.org/gfhr_pub/assoc/s14881e/s14881e.pdf.

Don
________________________
Donald W. Light
Cell: 609-216-0071
Professor, UMDNJ-SOM
Lokey visiting professor, Stanford University
Visiting researcher, CMD, Princeton University
Donald Light <dlight@princeton.edu>

<Prev in Thread] Current Thread [Next in Thread>